Arrowhead Pharmaceuticals Achieves FDA Approval for Rodemplo, Reports Strong Financial Turnaround
Key Insights
Arrowhead Pharmaceuticals received FDA approval for Rodemplo (search), its first approved medicine for treating familial chylomicronemia syndrome (search) (FCS) with a $60,000 annual WAC price.
The company reported a dramatic financial turnaround with only $2 million net loss in fiscal 2025 compared to $599 million loss in 2024, driven by $829 million in revenue from licensing agreements.
Arrowhead secured significant milestone payments including $200 million from Sarepta (search) and $200 million upfront from Novartis, with potential future payments up to $2 billion.
Arrowhead Pharmaceuticals achieved a major milestone with FDA approval of Rodemplo (search), marking the company's transition to commercial stage operations while reporting a dramatic financial turnaround that positions it for sustained growth through fiscal year 2028.
FDA Approval Marks Commercial Transition
The FDA approved Rodemplo (search) as an adjunct to diet for reducing triglycerides (search) in adults with familial chylomicronemia syndrome (search) (FCS), representing Arrowhead's first FDA-approved medicine. The company set the annual wholesale acquisition cost (WAC) price at $60,000, reflecting the drug's positioning as a best-in-class treatment.
According to Andy Davis, Senior Vice President, Arrowhead has "high ambitions for Redemplo, expecting it to be best in class due to its significant TG reduction, reduced pancreatitis incidence, favorable safety profile, and convenient dosing." These attributes differentiate Rodemplo (search) from existing treatments and support expectations for a strong commercial launch.
Financial Performance Shows Dramatic Improvement
Arrowhead reported a near breakeven result with a net loss of only $2 million for fiscal year 2025, representing a remarkable improvement from the $599 million net loss recorded in fiscal year 2024. This turnaround was driven by $829 million in revenue from license and collaboration agreements, demonstrating the company's successful strategic partnerships and strong financial management.
The company secured substantial milestone payments including $200 million from Sarepta (search) and $200 million upfront from Novartis for licensing collaboration agreements. These payments, combined with potential future milestone payments of up to $2 billion, reflect the value of Arrowhead's technology platform and pipeline assets.
Pipeline Advancement Across Multiple Therapeutic Areas
Arrowhead is making significant progress across its pipeline programs, with Phase III trials ongoing for Zidaziran (search) and Aerodimer PA (search). The company plans to complete the Shasta 3 and Shasta 4 Phase III studies by mid-2026, with top-line data expected in the second half of 2026. Plans include submitting a supplemental New Drug Application (sNDA) by the end of 2026.
The company is expanding into central nervous system therapeutics with ARO MAPT (search) for tauopathies (search) and Alzheimer's disease (search). James Hamilton, Chief Medical Officer, explained that unlike previous failed approaches, "our approach uses a targeting ligand to deliver siRNA across the blood-brain barrier, silencing tau (search) expression intracellularly. This method aims to prevent neurofibrillary tangles by reducing both intracellular and extracellular tau."
Obesity Programs Face Timeline Delays
Arrowhead faces challenges with delays in early data sharing from its obesity programs ARO INHBE (search) and ARO LK7 (search), now expected in early 2026. For ARO INHBE, the company will provide biomarker, MRI, and safety data from both monotherapy and combination cohorts, while ARO LK7 will focus on monotherapy safety and target knockdown data. More comprehensive results are expected later in 2026.
Addressing Large Unmet Medical Needs
The company's dimer program aims to treat mixed hyperlipidemia (search) by simultaneously lowering LDL cholesterol and triglycerides (search). Chris Anzalone, CEO, noted that "this approach could address a large unmet need in a population of 20 million in the US. We plan to move quickly into pivotal studies if phase 1/2 results are promising."
Regulatory Challenges Remain
Arrowhead has not yet engaged with the FDA regarding a pancreatitis risk reduction claim for Rodemplo (search), particularly for the high-risk severe hypertriglyceridemia patient population. This uncertainty presents a regulatory challenge that the company will need to address to fully capitalize on Rodemplo's therapeutic potential.
With a cash runway extending into fiscal year 2028 and multiple data readouts expected in 2026, Arrowhead is positioned for continued growth as it transitions from a development-stage to a commercial-stage biopharmaceutical company.